Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
September 30th, 2019
7.5K views
Herein, we present a detailed protocol for screening small peptides that bind to FGFR2 using a phage display peptide library. We further analyze the affinity of the selected peptides toward FGFR2 in vitro and its ability to suppress cell proliferation.
Overview
This article presents a protocol for screening small peptides that bind to FGFR2 using a phage display peptide library. The study further analyzes the affinity of selected peptides toward FGFR2 in vitro and their ability to suppress cell proliferation.
Key Study Components
Area of Science
- Neuroscience
- Biochemistry
- Pharmacology
Background
- FGFR2 is a critical receptor involved in various cellular processes.
- Identifying peptides that bind to FGFR2 can lead to new therapeutic strategies.
- Phage display technology is a powerful tool for peptide screening.
- This protocol aims to simplify the identification of FGFR2 modulators.
Purpose of Study
- To develop an efficient method for screening peptides that interact with FGFR2.
- To evaluate the binding affinity of selected peptides.
- To assess the biological effects of these peptides on cell proliferation.
Methods Used
- Preparation of FGFR2 in coating buffer.
- Use of a phage display peptide library for screening.
- In vitro affinity analysis of selected peptides.
- Assessment of cell proliferation suppression.
Main Results
- Identification of several peptides with high affinity for FGFR2.
- Demonstration of the ability of selected peptides to inhibit cell proliferation.
- Comparison of this protocol's efficiency with other methods.
- Successful integration of high throughput screening with ITC analysis.
Conclusions
- The protocol provides a reliable method for discovering FGFR2 modulators.
- It is efficient, economical, and user-friendly.
- This approach can facilitate further research into FGFR2-related therapies.
Frequently Asked Questions
What is FGFR2?
FGFR2 is a fibroblast growth factor receptor involved in cell signaling and proliferation.
How does phage display work?
Phage display involves displaying peptides on the surface of phages to identify binding interactions.
What are the advantages of this protocol?
It is easier, more efficient, and does not require prior knowledge of the target protein's structure.
Can this method be applied to other proteins?
Yes, the protocol can be adapted for screening peptides against various target proteins.
What are the potential applications of the identified peptides?
They may serve as therapeutic agents or research tools in studying FGFR2 functions.
Executive Industry Relevance
Phage display screening for FGFR2-binding peptides addresses a critical early discovery challenge in identifying novel modulators for oncology and cell signaling targets. This protocol enables rapid, high-throughput identification and quantitative characterization of peptide antagonists, supporting predictive confidence and mechanistic de-risking at the target validation stage. The approach is positioned to streamline portfolio triage and accelerate the advancement of peptide-based therapeutic candidates.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of FGFR2 as a disease-relevant target without prior structural knowledge.
- Supports functional validation of peptide antagonists through quantitative affinity and biological activity assays.
- Facilitates mechanistic de-risking by isolating specific peptide-receptor interactions.
- Improves predictive confidence for downstream therapeutic development decisions.
Screening & Assay Development
- Delivers validated peptide candidates for use in standardized binding and functional assays.
- Enables reproducible, high-throughput screening with scalable phage display libraries.
- Provides quantitative outputs via ITC and cell proliferation assays for robust compound evaluation.
- Supports assay platform reuse for other receptor or ligand targets.
Translational & Preclinical Research
- Aligns peptide discovery with disease-relevant FGFR2 signaling pathways implicated in oncology.
- Establishes continuity from molecular screening to preclinical functional validation.
- Reduces translational risk by confirming biological activity in cell-based assays.
- Enables risk-adjusted advancement of peptide leads into preclinical models.
Pipeline & Workflow Integration
This protocol integrates into the discovery continuum from early target validation through lead identification and preclinical evaluation for FGFR2-modulating peptides.
- Discovery Biology: Supports hypothesis testing and pathway clarification for FGFR2-driven disease mechanisms.
- Screening: Provides assay-ready peptide candidates with reproducible, quantitative binding data.
- Analytics: Delivers affinity measurements and cell-based functional readouts to compare peptide efficacy.
- Translational Research: Bridges molecular screening with preclinical validation in disease-relevant systems.
- Enterprise Reuse: Offers a scalable, adaptable platform for peptide screening across diverse targets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in FGFR2 targeting.
- Operational Value: Standardizes and streamlines peptide screening and validation workflows.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of peptide-based assets.
Implementation Considerations
- Requires expertise in phage display, peptide chemistry, and quantitative binding assays.
- Needs access to ITC instrumentation and cell-based assay infrastructure.
- Demands rigorous cross-team standardization to ensure reproducibility and data integrity.
- Adaptable to other receptor or ligand targets with appropriate library and assay modifications.
- Contamination control and precise handling are critical to avoid wild-type phage interference.
Biopharma FAQs
Why does null hypothesis testing matter for FGFR2 peptide screening?
Null hypothesis testing ensures that observed peptide-FGFR2 binding and biological effects are statistically significant, reducing false positives and increasing confidence in target validation decisions.
How does independent variable isolation fit in phage display rounds?
Isolating the variable of peptide sequence during iterative biopanning rounds allows clear attribution of binding and activity to specific peptides, supporting robust discovery pipeline progression.
What do quantitative ITC and proliferation assays enable in this workflow?
Quantitative ITC and cell proliferation assays provide precise affinity and functional data, enabling direct comparison of peptide candidates and supporting data-driven lead selection.
Why are replication requirements critical for cross-functional peptide evaluation?
Replication across screening and functional assays ensures reproducibility, enabling reliable cross-team data sharing and collaborative decision-making in R&D pipelines.
What statistical analysis capabilities are needed before peptide advancement?
Robust statistical analysis of binding and biological activity data is required to confirm significance, guide lead prioritization, and justify advancement into preclinical development.
Chapters in this video
0:04
Title
0:54
First Round of Biopanning: Screening Phage Clones that Bind to the Extracellular Domain of FGFR2
2:26
Titer Determination of the Eluted Phages
3:28
Phage Amplification
5:38
Results: Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2
6:38
Conclusion
